Knowledge of the molecular subtype has important implications for therapeutic strategies: in SDH-deficient GISTs, tumor, and germline SDH-complex genes (A, B, C, or D) sequencing should be performed; in tumors lacking the SDH mutation, the presence or absence of SDHC promoter methylation should be assessed. Here, SDHB is linked to neoplasm.